Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Waverley Pharma Inc.

Market Cap 810K 577K 498K 458K 431K 54.49M 817K 5.43M 2.11M 26.74M 2.17M 2.12M 92.52M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.21M 3M 2.59M 2.38M 2.24M 283M 4.24M 28.2M 10.98M 139M 11.26M 11.02M 481M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 day+50.00%
Current month+50.00%
1 month+50.00%
3 months-40.00%
Current year-25.00%
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.14
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 01/02/2020
Director of Finance/CFO - 01/01/2020
Director TitleAgeSince
Chairman 79 14/12/2016
Director/Board Member 54 14/12/2016
Director/Board Member - 22/11/2023
Date Insider Type Main position Quantity % Market Cap.
24/06/24Other

Director

0 0%
18/08/21Other

Chairman

0 0%
18/08/21Option

Chairman

10,000,000 18.5185%
Change 5-day change 1-year change 3-year change Capi.($)
+50.00%0.00%0.00%-57.14% 579K
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+2.73%+6.31%-12.75%-16.70% 22.63B
+5.95%+6.44%-2.48%+383.89% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
-2.54%-0.57%+26.42%+176.03% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-7.73%+6.58%+79.67%+104.65% 11.56B
Average +5.81%+0.63%+23.27%+73.94% 20.97B
Weighted average by Cap. +1.39%+0.51%+32.03%+90.05%

Financials

2024 2025
Net sales 475K 339K 292K 269K 253K 31.98M 479K 3.19M 1.24M 15.7M 1.27M 1.24M 54.3M 1.35M 962K 830K 763K 718K 90.79M 1.36M 9.04M 3.52M 44.56M 3.61M 3.53M 154M
Net income -947K -675K -582K -535K -504K -63.71M -955K -6.35M -2.47M -31.27M -2.53M -2.48M -108M -499K -356K -307K -282K -266K -33.58M -503K -3.34M -1.3M -16.48M -1.34M -1.31M -57.02M
Net Debt 2.83M 2.02M 1.74M 1.6M 1.51M 190M 2.85M 18.97M 7.38M 93.45M 7.57M 7.41M 323M 3.4M 2.42M 2.09M 1.92M 1.81M 229M 3.43M 22.78M 8.87M 112M 9.1M 8.9M 388M
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. WAVE Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!